Table 3 Univariate analysis for 8-year RFS and OS in (A) all patients according to CatS or treatment status, (B) treatment subgroups according to CatS and (C) CatS-stratified subgroups according to treatment

From: The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study

  8-year RFS 8-year OS
  % HR 95% CI P % HR 95%CI P
(A)         
 CatS (n=211)         
Low 63     63    
Moderate 63 1.22 0.88–1.69 0.23 62 1.11 0.79–1.55 0.54
 High 54     62    
 Treatment (n=211)         
Untreated 56 0.75 0.48–1.17 0.20 55 0.71 0.45–1.13 0.15
Treated 64     68    
(B)         
 Untreated (n=106)         
Low 67     65    
Moderate 57 1.72 1.13–2.66 0.01 53 1.62 1.05–2.51 0.03
High 32     38    
 Treated (n=105)         
Low 60     61    
Moderate 68 0.84 0.51–1.39 0.50 70 0.74 0.44–1.26 0.27
High 64     73    
(C)         
 Low (n=66)         
Untreated 67 1.34 0.60–3.19 0.45 65    
Treated 60     61 1.33 0.56–3.15 0.52
 Moderate (n=109)         
Untreated 57 0.69 0.37–1.30 0.25 53 0.70 0.37–1.34 0.28
Treated 68     70    
 High (n=36)         
Untreated 32 0.33 0.12–0.89 0.03 38 0.25 0.08–0.81 0.02
Treated 64     73    
  1. Abbreviations: CatS=Cathepsin S; CI=confidence interval; OS=overall survival; treated=patients treated with adjuvant fluorouracil/folinic acid; RFS=recurrence-free survival; untreated=patients receiving no adjuvant chemotherapy.